Imaging and Clinical Biomarker Estimation in Alzheimer’s Disease
Ani Eloyan · Jan 19, 2024
Date: 2024-01-19
Time: 15:30-16:30 (Montreal time)
Location: Online, retransmitted in Burnside 1104
https://mcgill.zoom.us/j/85422946487
Meeting ID: 854 2294 6487
Passcode: None
Abstract:
Estimation of biomarkers related to disease classification and modeling of its progression is essential for treatment development for Alzheimer’s Disease (AD). The task is more daunting for characterizing relatively rare AD subtypes such as the early-onset AD. In this talk, I will describe the Longitudinal Alzheimer’s Disease Study (LEADS) intending to collect and publicly distribute clinical, imaging, genetic, and other types of data from people with EOAD, as well as cognitively normal (CN) controls and people with early-onset non-amyloid positive (EOnonAD) dementias. I will discuss manifold estimation methods for estimation of surfaces of shapes in the brain using data clouds, longitudinal manifold learning methods for modeling trajectories of shape changes in the brain over time. Finally, I will discuss our work in leveraging magnetic resonance imaging and positron emission tomography data to characterize distributions of white matter hyperintensities in people with EOAD and to obtain imaging-based biomarkers of disease trajectories of AD subtypes.